Trial Profile
Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPD; a Non-interventional Switch Study to Evaluate the Impact on Clinical Effects, Patient's Satisfaction, Preference and Use of Easyhaler
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Mar 2020
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms SUNNY
- Sponsors Orion; Orion Pharma
- 27 Feb 2020 Status changed from active, no longer recruiting to completed.
- 16 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 01 Oct 2019 Planned End Date changed from 1 Nov 2019 to 1 Feb 2020.